EDUARDO LUNA
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
- Where
- EDINBURG, TX
- NPI
- 1073959326
- Received
- $1,366,082 in 2,548 records, 2019 to 2025 ($1,285,306 general, $80,776 research)
- As principal investigator
- $6,335,075 of research payments to others in 98 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 546 | $299,262 |
| 2024 | General payment | 556 | $297,010 |
| 2024 | Research payment | 13 | $42,164 |
| 2023 | General payment | 492 | $270,032 |
| 2023 | Research payment | 5 | $22,795 |
| 2022 | General payment | 405 | $215,937 |
| 2022 | Research payment | 4 | $15,816 |
| 2021 | General payment | 250 | $119,322 |
| 2020 | General payment | 131 | $58,996 |
| 2019 | General payment | 146 | $24,743 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 707 | $792,216 |
| Travel and Lodging | 435 | $220,381 |
| Compensation for serving as faculty or as a speaker for a medical education program | 91 | $120,925 |
| Research payment | 22 | $80,776 |
| Honoraria | 28 | $55,100 |
| Food and Beverage | 1,168 | $41,247 |
| Consulting Fee | 19 | $30,680 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 33 | $23,756 |
| Education | 45 | $997 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-29 | Ascensia Diabetes Care Us Inc. | $13 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-19 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-12-18 | RECORDATI_RARE_DISEASES_INC. | $120 | Food and Beverage | In-kind items and services | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-12-18 | Dexcom, Inc. | $48 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2025 | |
| 2025-12-17 | Amgen Inc. | $20 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-12-16 | Lilly USA, LLC | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-16 | Corcept Therapeutics | $23 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-12-15 | Alexion Pharmaceuticals, Inc. | $26 | Food and Beverage | In-kind items and services | STRENSIQ Biological, Rare Disease | 2025 | |
| 2025-12-12 | Insulet Corporation | $706 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-12-10 | Bayer Healthcare Pharmaceuticals Inc. | $1,715 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Lynkuet Drug, Womens Health | 2025 | |
| 2025-12-08 | Madrigal Pharmaceuticals | $6,640 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-05 | Lilly USA, LLC | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-05 | Corcept Therapeutics | $3 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-12-04 | Insulet Corporation | $706 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-12-04 | Lilly USA, LLC | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-03 | Corcept Therapeutics | $1 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-12-02 | Madrigal Pharmaceuticals | $42 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-01 | Lilly USA, LLC | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-26 | Lilly USA, LLC | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-26 | Corcept Therapeutics | $11 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-11-25 | Dexcom, Inc. | $39 | Food and Beverage | In-kind items and services | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | 2025 | |
| 2025-11-25 | Novo Nordisk Inc | $12 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2025 | |
| 2025-11-24 | Dexcom, Inc. | $1,915 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | 2025 | |
| 2025-11-24 | Regeneron Healthcare Solutions, Inc. | $35 | Food and Beverage | In-kind items and services | EVKEEZA Biological, CARDIOVASCULAR AND METABOLIC | 2025 | |
| 2025-11-20 | Lilly USA, LLC | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-20 | Abbott Laboratories | $15 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-11-19 | Corcept Therapeutics | $2,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-11-19 | Mannkind Corporation | $24 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2025 | |
| 2025-11-19 | Novo Nordisk Inc | $8 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2025 | |
| 2025-11-17 | Lilly USA, LLC | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-11-14 | Dexcom, Inc. | $22 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2025 | |
| 2025-11-13 | Corcept Therapeutics | $147 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-11-13 | Insulet Corporation | $58 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-11-13 | Corcept Therapeutics | $5 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-11-12 | Lilly USA, LLC | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-10 | Corcept Therapeutics | $27 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-11-06 | Madrigal Pharmaceuticals | $3,528 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-11-06 | Madrigal Pharmaceuticals | $536 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-11-06 | Madrigal Pharmaceuticals | $453 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-11-04 | Dexcom, Inc. | $1,915 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | DEXCOM G7 GSS (161) Medical Supply, Endocrinology | 2025 | |
| 2025-11-04 | Corcept Therapeutics | $10 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-10-30 | Lilly USA, LLC | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-30 | Dexcom, Inc. | $22 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2025 | |
| 2025-10-30 | Corcept Therapeutics | $8 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-10-29 | RECORDATI_RARE_DISEASES_INC. | $119 | Food and Beverage | In-kind items and services | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-10-29 | Mannkind Corporation | $23 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2025 | |
| 2025-10-27 | Lilly USA, LLC | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-27 | Lilly USA, LLC | $875 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-24 | Lilly USA, LLC | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-24 | Lilly USA, LLC | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-24 | Novo Nordisk Inc | $8 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-10-23 | Corcept Therapeutics | $11 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-10-22 | Corcept Therapeutics | $1,820 | Honoraria | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-10-22 | Amgen Inc. | $8 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-10-21 | Lilly USA, LLC | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-21 | Lilly USA, LLC | $115 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-10-21 | RECORDATI_RARE_DISEASES_INC. | $18 | Food and Beverage | In-kind items and services | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-10-21 | RECORDATI_RARE_DISEASES_INC. | $1 | Food and Beverage | In-kind items and services | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-10-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20 | Food and Beverage (2 payments) | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-10-17 | Abbott Laboratories | $562 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-10-17 | Abbott Laboratories | $187 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-10-15 | Ascensia Diabetes Care Us Inc. | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-15 | Insulet Corporation | $13 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2025 | |
| 2025-10-15 | Xeris Pharmaceuticals, Inc. | $12 | Food and Beverage | In-kind items and services | GVOKE HYPOPEN Drug, Diabetes | 2025 | |
| 2025-10-13 | Abbott Laboratories | $9 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-10-10 | RECORDATI_RARE_DISEASES_INC. | $2,723 | Honoraria | Cash or cash equivalent | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-10-10 | RECORDATI_RARE_DISEASES_INC. | $928 | Travel and Lodging | Cash or cash equivalent | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-10-10 | RECORDATI_RARE_DISEASES_INC. | $232 | Food and Beverage | Cash or cash equivalent | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-10-10 | RECORDATI_RARE_DISEASES_INC. | $39 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-10-10 | Dexcom, Inc. | $10 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2025 | |
| 2025-10-09 | RECORDATI_RARE_DISEASES_INC. | $200 | Travel and Lodging | Cash or cash equivalent | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-10-09 | RECORDATI_RARE_DISEASES_INC. | $137 | Food and Beverage | Cash or cash equivalent | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-10-09 | Amgen Inc. | $20 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-10-08 | RECORDATI_RARE_DISEASES_INC. | $158 | Food and Beverage | In-kind items and services | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-10-08 | Corcept Therapeutics | $35 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-10-08 | Bayer Healthcare Pharmaceuticals Inc. | $18 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-06 | RECORDATI_RARE_DISEASES_INC. | $532 | Honoraria | Cash or cash equivalent | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-10-06 | Corcept Therapeutics | $20 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-10-03 | Lilly USA, LLC | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-02 | Insulet Corporation | $3,325 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-10-02 | Alexion Pharmaceuticals, Inc. | $870 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-01 | Ascensia Diabetes Care Us Inc. | $15 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-30 | RECORDATI_RARE_DISEASES_INC. | $3,281 | Honoraria | Cash or cash equivalent | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-09-30 | Amgen Inc. | $16 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-09-30 | Novo Nordisk Inc | $7 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-09-26 | RECORDATI_RARE_DISEASES_INC. | $750 | Honoraria | Cash or cash equivalent | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-09-26 | RECORDATI_RARE_DISEASES_INC. | $468 | Honoraria | Cash or cash equivalent | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-09-26 | Xeris Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | RECORLEV Drug, Adrenal steroidogenesis inhibitor | 2025 | |
| 2025-09-25 | Corcept Therapeutics | $4,995 | Honoraria | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-25 | Mannkind Corporation | $19 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2025 | |
| 2025-09-22 | Amgen Inc. | $26 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-09-20 | Corcept Therapeutics | $79 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-20 | Corcept Therapeutics | $64 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-20 | Corcept Therapeutics | $41 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-20 | Corcept Therapeutics | $41 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-20 | Corcept Therapeutics | $30 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-19 | Corcept Therapeutics | $486 | Travel and Lodging | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-19 | Corcept Therapeutics | $258 | Travel and Lodging | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-19 | Corcept Therapeutics | $150 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-19 | Corcept Therapeutics | $46 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-18 | Dexcom, Inc. | $22 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2025 | |
| 2025-09-18 | Abbott Laboratories | $4 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2025 | |
| 2025-09-16 | Novartis Pharmaceuticals Corporation | $15 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-09-16 | Lilly USA, LLC | $4 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-09-15 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-09-15 | Lilly USA, LLC | $3 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-09-13 | Insulet Corporation | $284 | Travel and Lodging | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-09-13 | Insulet Corporation | $145 | Travel and Lodging | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-09-13 | Insulet Corporation | $107 | Travel and Lodging | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-09-13 | Insulet Corporation | $25 | Food and Beverage | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-09-13 | Insulet Corporation | $17 | Food and Beverage | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-09-13 | Insulet Corporation | $7 | Food and Beverage | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-09-12 | Insulet Corporation | $380 | Travel and Lodging | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-09-12 | Abbott Laboratories | $375 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-09-12 | Insulet Corporation | $374 | Travel and Lodging | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-09-12 | Insulet Corporation | $289 | Travel and Lodging | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-09-12 | Insulet Corporation | $133 | Food and Beverage | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-09-12 | Insulet Corporation | $30 | Food and Beverage | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-09-11 | Insulet Corporation | $1,575 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-09-11 | Insulet Corporation | $1,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-09-11 | Xeris Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | GVOKE HYPOPEN Drug, Diabetes | 2025 | |
| 2025-09-10 | Alexion Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | STRENSIQ Biological, Rare Disease | 2025 | |
| 2025-09-09 | RECORDATI_RARE_DISEASES_INC. | $2,062 | Honoraria | Cash or cash equivalent | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-09-09 | RECORDATI_RARE_DISEASES_INC. | $100 | Food and Beverage | In-kind items and services | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-09-09 | Corcept Therapeutics | $6 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-08 | Soleno Therapeutics, Inc. | $30 | Food and Beverage | In-kind items and services | VYKAT XR Drug, Prader-Willi syndrome | 2025 | |
| 2025-09-06 | Lilly USA, LLC | $23 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-09-06 | Lilly USA, LLC | $0 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-09-05 | Madrigal Pharmaceuticals | $830 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-09-05 | Xeris Pharmaceuticals, Inc. | $295 | Honoraria | Cash or cash equivalent | RECORLEV Drug, Adrenal steroidogenesis inhibitor | 2025 | |
| 2025-09-05 | Lilly USA, LLC | $0 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-09-04 | RECORDATI_RARE_DISEASES_INC. | $2,437 | Honoraria | Cash or cash equivalent | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-09-04 | Lilly USA, LLC | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-09-04 | Lilly USA, LLC | $28 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-09-04 | Amgen Inc. | $12 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-09-03 | Corcept Therapeutics | $12 | Food and Beverage | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-02 | RECORDATI_RARE_DISEASES_INC. | $1,713 | Travel and Lodging | Cash or cash equivalent | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-09-02 | Insulet Corporation | $60 | Travel and Lodging | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-09-02 | Lilly USA, LLC | $26 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-08-28 | Insulet Corporation | $104 | Food and Beverage | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-08-28 | Insulet Corporation | $15 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2025 | |
| 2025-08-27 | Corcept Therapeutics | $45 | Food and Beverage | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-08-27 | Corcept Therapeutics | $20 | Travel and Lodging | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-08-27 | Ascensia Diabetes Care Us Inc. | $10 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-25 | Radius Health, Inc. | $26 | Food and Beverage | In-kind items and services | Tymlos Drug, Endocrinology | 2025 | |
| 2025-08-25 | Bayer Healthcare Pharmaceuticals Inc. | $8 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-22 | RECORDATI_RARE_DISEASES_INC. | $2,062 | Honoraria | Cash or cash equivalent | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-08-22 | Lilly USA, LLC | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-08-21 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-08-19 | RECORDATI_RARE_DISEASES_INC. | $31 | Food and Beverage | In-kind items and services | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-08-19 | Corcept Therapeutics | $9 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-08-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-08-15 | Lilly USA, LLC | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-08-14 | Lilly USA, LLC | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-08-14 | Amgen Inc. | $26 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-08-13 | Corcept Therapeutics | $4,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-08-13 | RECORDATI_RARE_DISEASES_INC. | $2,250 | Honoraria | Cash or cash equivalent | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-08-13 | RECORDATI_RARE_DISEASES_INC. | $153 | Food and Beverage | In-kind items and services | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-08-13 | RECORDATI_RARE_DISEASES_INC. | $10 | Travel and Lodging | Cash or cash equivalent | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-08-12 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-08-11 | Mannkind Corporation | $16 | Food and Beverage | In-kind items and services | AFREZZA Drug, DIABETES MEDICINE | 2025 | |
| 2025-08-08 | Lilly USA, LLC | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-08-08 | Lilly USA, LLC | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-08-07 | Corcept Therapeutics | $1,524 | Travel and Lodging | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-08-07 | Corcept Therapeutics | $131 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-08-07 | Ascensia Diabetes Care Us Inc. | $5 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-06 | Corcept Therapeutics | $4,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-08-05 | Madrigal Pharmaceuticals | $1,245 | Consulting Fee | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-08-05 | Corcept Therapeutics | $28 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-08-04 | Lilly USA, LLC | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-08-04 | Dexcom, Inc. | $10 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2025 | |
| 2025-08-01 | Xeris Pharmaceuticals, Inc. | $1,180 | Honoraria | Cash or cash equivalent | RECORLEV Drug, Adrenal steroidogenesis inhibitor | 2025 | |
| 2025-08-01 | Bayer Healthcare Pharmaceuticals Inc. | $27 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-01 | Bayer Healthcare Pharmaceuticals Inc. | $2 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-07-31 | Corcept Therapeutics | $1,936 | Travel and Lodging | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-07-31 | Insulet Corporation | $706 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-07-31 | Senseonics, Incorporated | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Eversense Device, Endocrinology | 2025 | |
| 2025-07-31 | Senseonics, Incorporated | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Eversense Device, Endocrinology | 2025 | |
| 2025-07-31 | Corcept Therapeutics | $140 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-07-30 | Lilly USA, LLC | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-07-30 | RECORDATI_RARE_DISEASES_INC. | $5 | Food and Beverage | In-kind items and services | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-07-29 | Novartis Pharmaceuticals Corporation | $27 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-07-25 | RECORDATI_RARE_DISEASES_INC. | $28 | Food and Beverage | In-kind items and services | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-07-25 | Corcept Therapeutics | $18 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-07-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | $21 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-07-24 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-07-23 | RECORDATI_RARE_DISEASES_INC. | $3,562 | Honoraria | Cash or cash equivalent | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-07-23 | RECORDATI_RARE_DISEASES_INC. | $277 | Travel and Lodging | Cash or cash equivalent | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-07-23 | RECORDATI_RARE_DISEASES_INC. | $36 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-07-22 | RECORDATI_RARE_DISEASES_INC. | $225 | Travel and Lodging | Cash or cash equivalent | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-07-22 | Radius Health, Inc. | $32 | Food and Beverage | In-kind items and services | Tymlos Drug, Endocrinology | 2025 | |
| 2025-07-21 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-07-18 | Abbott Laboratories | $121 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-07-16 | Lilly USA, LLC | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-07-16 | Lilly USA, LLC | $525 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-07-16 | Corcept Therapeutics | $7 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-07-15 | Esperion Therapeutics, Inc. | $15 | Food and Beverage | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2025 | |
| 2025-07-12 | Corcept Therapeutics | $93 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-07-12 | Corcept Therapeutics | $84 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 |
The latest 200 records of 2,548.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH | $7,968 | A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and sa | 2025 |
| 2025-12-17 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $934 | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WI | 2025 |
| 2025-12-17 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $915 | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WI | 2025 |
| 2025-12-05 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH LLC | $4,820 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-11-10 | Amgen Inc. | TEXAS VALLEY CLINICAL RESEARCH | $306 | A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, an | 2025 |
| 2025-11-05 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH LLC | $24,228 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-10-09 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH LLC | $8,672 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-10-09 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH LLC | $4,338 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-10-09 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH LLC | $12,328 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-09-04 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH LLC | $21,984 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-08-06 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH LLC | $19,833 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-07-28 | Novartis Pharmaceuticals Corporation | COMPREHENSIVE CENTER | $7,823 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2025 |
| 2025-07-02 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH LLC | $9,698 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-06-03 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH LLC | $39,732 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-05-12 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $143,697 | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND L | 2025 |
| 2025-05-07 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH LLC | $13,713 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-05-06 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $155,888 | A PARALLEL-GROUP TREATMENT, PHASE 2, DOUBLE-BLIND STUDY OF ONCE-WEEKLY SUBCUTANEOUS LY3457263 COMPARED TO PLACEBO IN PAR | 2025 |
| 2025-04-03 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH LLC | $4,308 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-03-07 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH LLC | $10,449 | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of | 2025 |
| 2025-02-11 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $15,100 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2025 |
| 2025-02-06 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH LLC | $28,311 | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of | 2025 |
| 2025-02-03 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $610,508 | A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY C | 2025 |
| 2025-02-03 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $81,790 | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY | 2025 |
| 2025-01-31 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $3,364 | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2025 |
| 2025-01-31 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $10,300 | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH P | 2025 |
| 2025-01-31 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $3,812 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2025 |
| 2025-01-31 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $1,552 | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY | 2025 |
| 2025-01-28 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $364,700 | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR THE TREATMENT OF OBESITY AND WEIGHT-RELATED COMORBIDIT | 2025 |
| 2025-01-24 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $11,658 | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR THE TREATMENT OF OBESITY AND WEIGHT-RELATED COMORBIDIT | 2025 |
| 2025-01-24 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $3,235 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION | 2025 |
| 2025-01-21 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $114,332 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2025 |
| 2025-01-21 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $102,825 | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2025 |
| 2025-01-21 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $119,034 | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY | 2025 |
| 2025-01-21 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $2,557 | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT I | 2025 |
| 2025-01-21 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $113,072 | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT I | 2025 |
| 2025-01-20 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $2,144 | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT I | 2025 |
| 2025-01-09 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $3,372 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2025 |
| 2025-01-09 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $13,833 | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TI | 2025 |
| 2025-01-07 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $49,694 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION | 2025 |
| 2025-01-07 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $42,958 | A STUDY OF ORFORGLIPRON (LY3502970) IN PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH INSULIN GL | 2025 |
| 2025-01-07 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $299,948 | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH P | 2025 |
| 2025-01-07 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $617,110 | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TI | 2025 |
| 2025-01-03 | Eli Lilly Export S.A. Puerto Rico Branch | TEXAS VALLEY CLINICAL RESEARCH LLC | $3,530 | A STUDY OF ORFORGLIPRON (LY3502970) IN PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH INSULIN GL | 2025 |
| 2025-01-02 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $4,523 | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY | 2025 |
| 2025-01-02 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $8,852 | A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY C | 2025 |
| 2024-12-31 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH LLC | $6,760 | M21-341 ATH Ph 2b Armour Thyroid vs Synthetic T4 (ATH-MD-01) (3014-301-002) | 2024 |
| 2024-12-30 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH LLC | $12,842 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-12-05 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH LLC | $18,584 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-11-18 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $24,100 | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY | 2024 |
| 2024-11-13 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $8,250 | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH P | 2024 |
| 2024-11-13 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $38,880 | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TI | 2024 |
| 2024-11-07 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH LLC | $36,965 | A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Sa | 2024 |
| 2024-11-01 | HARMONY BIOSCIENCES LLC | TEXAS VALLEY CLINICAL RESEARCH | $8,246 | A Phase 3, Randomized, Double-Blind, Placebo-controlled, Efficacy and Safety Study of Pitolisant Followed by an Open-Lab | 2024 |
| 2024-10-28 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH LLC | $4,375 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-10-22 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $65,225 | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT I | 2024 |
| 2024-10-16 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $2,097 | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH P | 2024 |
| 2024-10-03 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH LLC | $33,165 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-09-18 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $12,591 | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY | 2024 |
| 2024-09-16 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $3,246 | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TI | 2024 |
| 2024-09-04 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH LLC | $12,047 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-08-08 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $1,641 | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT I | 2024 |
| 2024-08-02 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH LLC | $11,303 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-07-10 | HARMONY BIOSCIENCES LLC | TEXAS VALLEY CLINICAL RESEARCH | $4,965 | A Phase 3, Randomized, Double-Blind, Placebo-controlled, Efficacy and Safety Study of Pitolisant Followed by an Open-Lab | 2024 |
| 2024-07-10 | HARMONY BIOSCIENCES LLC | TEXAS VALLEY CLINICAL RESEARCH | $2,000 | A Phase 3, Randomized, Double-Blind, Placebo-controlled, Efficacy and Safety Study of Pitolisant Followed by an Open-Lab | 2024 |
| 2024-06-20 | HARMONY BIOSCIENCES LLC | TEXAS VALLEY CLINICAL RESEARCH | $8,500 | A Phase 3, Randomized, Double-Blind, Placebo-controlled, Efficacy and Safety Study of Pitolisant Followed by an Open-Lab | 2024 |
| 2024-05-07 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $7,068 | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR THE TREATMENT OF OBESITY AND WEIGHT-RELATED COMORBIDIT | 2024 |
| 2024-04-15 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $171,554 | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY | 2024 |
| 2024-04-05 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $475,112 | A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY C | 2024 |
| 2024-04-05 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $158,513 | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR THE TREATMENT OF OBESITY AND WEIGHT-RELATED COMORBIDIT | 2024 |
| 2024-04-04 | ABBVIE INC. | TEXAS VALLEY CLINICAL RESEARCH LLC | $12,500 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-03-18 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $5,986 | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY | 2024 |
| 2024-02-13 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $216,098 | A STUDY OF ORFORGLIPRON (LY3502970) IN PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH INSULIN GL | 2024 |
| 2024-02-12 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $1,825 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION | 2024 |
| 2024-01-31 | Eli Lilly Export S.A. Puerto Rico Branch | TEXAS VALLEY CLINICAL RESEARCH LLC | $9,592 | A STUDY OF ORFORGLIPRON (LY3502970) IN PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH INSULIN GL | 2024 |
| 2024-01-30 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $6,293 | A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY C | 2024 |
| 2024-01-25 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $11,262 | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2024 |
| 2024-01-25 | Novartis Pharmaceuticals Corporation | COMPREHENSIVE CENTER | $24,025 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2024 |
| 2024-01-09 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $22,910 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2024 |
| 2024-01-09 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $389,339 | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2024 |
| 2024-01-09 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $11,591 | A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 ADMINI | 2024 |
| 2024-01-04 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $6,221 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2024 |
| 2024-01-02 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $90,587 | A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 ADMINI | 2024 |
| 2024-01-02 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $298,959 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2024 |
| 2024-01-02 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $64,999 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION | 2024 |
| 2024-01-02 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $129,175 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2024 |
| 2023-12-18 | Novartis Pharmaceuticals Corporation | COMPREHENSIVE CENTER RESEARCH | $245 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2023 |
| 2023-12-11 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $10,500 | A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH | 2023 |
| 2023-12-11 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $12,575 | A PHASE 3 RANDOMIZED DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED | 2023 |
| 2023-11-16 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $2,191 | A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH | 2023 |
| 2023-10-31 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $1,027 | A PHASE 3 RANDOMIZED DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED | 2023 |
| 2023-10-16 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $647 | A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF | 2023 |
| 2023-10-09 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $10,591 | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | 2023 |
| 2023-08-07 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $4,056 | A PHASE 3 PARALLEL-DESIGN OPEN-LABEL RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 ADMINISTE | 2023 |
| 2023-07-11 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $144,401 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 |
| 2023-05-02 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $82,151 | A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF | 2023 |
| 2023-05-02 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $232,856 | A PHASE 3 PARALLEL-DESIGN OPEN-LABEL RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 ADMINISTE | 2023 |
| 2023-05-01 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $462 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 |
| 2023-01-03 | Eli Lilly and Company | TEXAS VALLEY CLINICAL RESEARCH LLC | $280,211 | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Edinburg, TX, county Hidalgo County, TX, state Texas; placed by its city name.
| Measure | Place (city or town) Edinburg, TX | County Hidalgo County, TX | State Texas |
|---|---|---|---|
| Population B01003 | 104,550 | 891,977 | 30,188,424 |
| Population, 2020 census P1 | 100,243 | 870,781 | 29,145,505 |
| Median age B01002 | 30.2 | 30.5 | 35.6 |
| Under 18 B01001 | 27.7% | 31.0% | 25.0% |
| 65 and over B01001 | 9.8% | 11.7% | 13.4% |
| Households B11001 | 35,680 | 270,210 | 10,992,816 |
| Foreign born B05002 | 19.7% | 26.1% | 17.6% |
| Median household income B19013 | $59,466 | $54,338 | $78,476 |
| Median family income B19113 | $62,060 | $60,128 | $94,599 |
| Per capita income B19301 | $28,336 | $23,117 | $40,752 |
| Poverty rate B17001 | 26.0% | 26.7% | 13.8% |
| Unemployment rate B23025 | 6.1% | 7.6% | 5.3% |
| Civilian labor force B23025 | 48,220 | 382,422 | 15,233,563 |
| Mean commute (minutes) B08013 | 21.8 | 22.5 | 26.7 |
| Bachelor's degree or higher B15003 | 28.4% | 20.6% | 33.8% |
| Housing units B25001 | 39,242 | 308,556 | 12,128,515 |
| Owner-occupied B25003 | 53.3% | 67.5% | 62.6% |
| Renters B25003 | 46.7% | 32.5% | 37.4% |
| Median home value B25077 | $189,600 | $140,900 | $283,800 |
| Median gross rent B25064 | $996 | $957 | $1,403 |
| White, not Hispanic B03002 | 8.6% | 6.0% | 39.1% |
| Black B03002 | 1.4% | 0.6% | 11.9% |
| Hispanic or Latino B03002 | 86.7% | 91.9% | 39.7% |
| Asian B03002 | 2.6% | 1.0% | 5.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Edinburg, TX.
Comments